DGAP-News: Vita 34 AG: Successful Annual General Meeting with Notable Approval of Shareholders
(firmenpresse) - DGAP-News: Vita 34 AG / Key word(s): AGM/EGM
Vita 34 AG: Successful Annual General Meeting with Notable Approval of
Shareholders
25.07.2013 / 12:16
---------------------------------------------------------------------
Vita 34 AG: Successful Annual General Meeting with Notable Approval of
Shareholders
- Presence of capital stock totaled 32.78%.
- Management Board reported on fiscal year 2012 and confirmed positive
outlook for 2013
- Dr. Hans-Georg Giering elected as new Supervisory Board member
Leipzig, July 25, 2013 - Vita 34 AG (WKN A0BL84), Europe's oldest private
stem cell bank and a specialist for cryo-preservation, conducted its 2013
Annual General Meeting successfully in Leipzig today. Here, the presence of
capital stock represented was 32.78%. The company reported on the
development of business in the prior fiscal year 2012, and looked
optimistically towards the future.
Within the scope of the Annual General Meeting all agenda items were
accepted by a large majority of the shareholders present. Apart from a
change in the by-laws regarding the corporate purpose of Vita 34 AG in the
wake of the merger with BioPlanta GmbH, which became effective on November
30, 2012, when it was recorded in the corporate register, among other
things new elections to the Supervisory Board were on the agenda.
Supervisory Board member Dr. Uwe Marx resigned his position effective
today. Per nomination, Dr. Hans-Georg Giering was elected as his successor.
All of the Supervisory Board members and the Management Board in office in
fiscal year 2012 were granted discharge.
Dr. AndréGerth, Chairman of the Management Board of Vita 34 AG, explained
to the shareholders the measures initiated in 2012 for increasing
profitability, and took positive stock of the latest business developments:
'The cost reduction measures contributed significantly to the improvement
in the Vita 34 fiscal position in the first half-year 2013. We will
continue to expand our market presence in Europe with local cooperative
sales ventures and subsidiaries, and solidify our market leadership by
introducing new products.'
Dr. Gerth also confirmed the prognosis for fiscal year 2013: 'We expect a
clear increase in operating profit (EBITDA) to at least EUR 1 million in
the current year. We are very pleased that EBITDA in the first half-year
2013 is already higher than in the prior year's period.'
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood. The basis for its
successful work is an outstanding position in the technological segment of
cryo-preservation. Here, cells and tissues are preserved alive at
temperatures around minus 190 degrees Celsius, and can be used if needed in
the context of medical treatment. Parents of more than 95,000 children are
already taking advantage of this offering and have provided for their
children with a stem cell deposit at this Leipzig company.
End of Corporate News
---------------------------------------------------------------------
25.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir(at)vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
222834 25.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.07.2013 - 12:16 Uhr
Sprache: Deutsch
News-ID 281689
Anzahl Zeichen: 5526
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 334 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Vita 34 AG: Successful Annual General Meeting with Notable Approval of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Vita 34 AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
